BARDA Awards Vericel $197 Million for NexoBrid Development
VCEL sits 19% above its 52-week low of $28.95.
Summary
Vericel Corporation has secured a significant award valued at up to $197 million from the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development and procurement of its burn treatment product, NexoBrid. This substantial funding provides a material boost to the development and potential commercialization pathway for NexoBrid. The award de-risks future development costs and signals strong government support for the product, which is a key asset for Vericel. This news is a strong positive catalyst, likely to increase investor confidence and drive the stock higher.
At the time of this announcement, VCEL was trading at $34.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $28.95 to $45.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.